Literature DB >> 24509215

Fundamental characteristics of the expressed immunoglobulin VH and VL repertoire in different canine breeds in comparison with those of humans and mice.

Sebastian C J Steiniger1, William E Dunkle2, Gary F Bammert2, Thomas L Wilson2, Abhiram Krishnan3, Steven A Dunham2, Gregory C Ippolito4, Graeme Bainbridge2.   

Abstract

Complementarity determining regions (CDR) are responsible for binding antigen and provide substantial diversity to the antibody repertoire, with VH CDR3 of the immunoglobulin variable heavy (VH) domain playing a dominant role. In this study, we examined 1200 unique canine VH and 500 unique variable light (VL) sequences of large and small canine breeds derived from peripheral B cells. Unlike the human and murine repertoire, the canine repertoire is heavily dominated by the Canis lupus familiaris IGHV1 subgroup, evolutionarily closest to the human IGHV3 subgroup. Our studies clearly show that the productive canine repertoire of all analyzed breeds shows similarities to both human and mouse; however, there are distinct differences in terms of VH CDR3 length and amino acid paratope composition. In comparison with the human and murine antibody repertoire, canine VH CDR3 regions are shorter in length than the human counterparts, but longer than the murine VH CDR3. Similar to corresponding human and mouse VH CDR3, the amino acids at the base of the VH CDR3 loop are strictly conserved. For identical CDR positions, there were significant changes in chemical paratope composition. Similar to human and mouse repertoires, the neutral amino acids tyrosine, glycine and serine dominate the canine VH CDR3 interval (comprising 35%) although the interval is nonetheless relatively depleted of tyrosine when compared to human and mouse. Furthermore, canine VH CDR3 displays an overrepresentation of the neutral amino acid threonine and the negatively charged aspartic acid while proline content is similar to that in the human repertoire. In general, the canine repertoire shows a bias towards small, negatively charged amino acids. Overall, this analysis suggests that functional canine therapeutic antibodies can be obtained from human and mouse sequences by methods of speciation and affinity maturation.
Copyright © 2014 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Amino acid composition; Antibody engineering; Canine antibody repertoire; Canine breeds; Immunoglobulin heavy chain complementary-determining region 3

Mesh:

Substances:

Year:  2014        PMID: 24509215     DOI: 10.1016/j.molimm.2014.01.010

Source DB:  PubMed          Journal:  Mol Immunol        ISSN: 0161-5890            Impact factor:   4.407


  5 in total

1.  A method for the isolation and characterization of functional murine monoclonal antibodies by single B cell cloning.

Authors:  Sara Carbonetti; Brian G Oliver; Vladimir Vigdorovich; Nicholas Dambrauskas; Brandon Sack; Emilee Bergl; Stefan H I Kappe; D Noah Sather
Journal:  J Immunol Methods       Date:  2017-05-26       Impact factor: 2.303

2.  Development and application of a next-generation sequencing protocol and bioinformatics pipeline for the comprehensive analysis of the canine immunoglobulin repertoire.

Authors:  Jonah N Cullen; Jolyon Martin; Albert J Vilella; Amy Treeful; David Sargan; Allan Bradley; Steven G Friedenberg
Journal:  PLoS One       Date:  2022-07-08       Impact factor: 3.752

3.  Deep Characterization of the Human Antibody Response to Natural Infection Using Longitudinal Immune Repertoire Sequencing.

Authors:  Erin M Mitsunaga; Michael P Snyder
Journal:  Mol Cell Proteomics       Date:  2019-11-25       Impact factor: 5.911

4.  Sequence analysis of feline immunoglobulin mRNAs and the development of a felinized monoclonal antibody specific to feline panleukopenia virus.

Authors:  Zhengchun Lu; Rebecca L Tallmadge; Heather M Callaway; M Julia B Felippe; John S L Parker
Journal:  Sci Rep       Date:  2017-10-05       Impact factor: 4.379

5.  Preferential use of unmutated immunoglobulin heavy variable region genes in Boxer dogs with chronic lymphocytic leukemia.

Authors:  Emily D Rout; Robert C Burnett; Julia D Labadie; Janna A Yoshimoto; Anne C Avery
Journal:  PLoS One       Date:  2018-01-31       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.